Y-mAbs Therapeutics, Inc. (YMAB)
- Previous Close
4.2500 - Open
4.2100 - Bid 3.7500 x 100
- Ask 4.0000 x 100
- Day's Range
3.8500 - 4.4600 - 52 Week Range
3.8400 - 16.1100 - Volume
326,467 - Avg. Volume
350,643 - Market Cap (intraday)
174.769M - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6700 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.10
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
www.ymabs.comRecent News: YMAB
View More
Performance Overview: YMAB
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: YMAB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: YMAB
View MoreValuation Measures
Market Cap
174.77M
Enterprise Value
108.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.95
Price/Book (mrq)
1.90
Enterprise Value/Revenue
1.24
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-33.83%
Return on Assets (ttm)
-12.67%
Return on Equity (ttm)
-30.74%
Revenue (ttm)
87.69M
Net Income Avi to Common (ttm)
-29.67M
Diluted EPS (ttm)
-0.6700
Balance Sheet and Cash Flow
Total Cash (mrq)
67.23M
Total Debt/Equity (mrq)
0.89%
Levered Free Cash Flow (ttm)
4.44M
Research Analysis: YMAB
View MoreResearch Reports: YMAB
View MoreDaily – Vickers Top Buyers & Sellers for 12/12/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/04/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 11/30/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 05/18/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.